Cite
HARVARD Citation
Celik, I. et al. (2021). Low‐dose tocilizumab is associated with improved outcome and a low risk of secondary infection in severe COVID‐19 pneumonia. International journal of clinical practice. 75 (12), p. n/a. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Celik, I. et al. (2021). Low‐dose tocilizumab is associated with improved outcome and a low risk of secondary infection in severe COVID‐19 pneumonia. International journal of clinical practice. 75 (12), p. n/a. [Online].